Amanta Healthcare IPO: Muted Debut Expected Despite Strong Subscription Buzz

As the Indian stock market opens today, all eyes are on Amanta Healthcare Ltd, whose equity shares are set to debut on both the BSE and NSE. Despite an overwhelming response during its initial public offering, market experts and grey market indicators suggest a modest listing for the pharmaceutical firm. The IPO listing marks a significant milestone for Amanta, but investor sentiment remains cautiously optimistic.

IPO Snapshot and Market Debut

Amanta Healthcare’s IPO was open for subscription from September 1 to 3, 2025, and saw an impressive overall subscription rate of 82.61 times. The allotment was finalized on September 4, and the shares are now listed under the T Group of Securities, with trading commencing at 10:00 AM today.

Key highlights:
- Issue size: ₹126 crore through a fresh issue of 1 crore equity shares
- Price band: ₹120 to ₹126 per share
- Listing date: September 9, 2025
- Exchanges: BSE and NSE
- Grey Market Premium (GMP): ₹9 per share, indicating an estimated listing price of ₹135

Despite the strong subscription numbers, the GMP signals a relatively muted debut, with a premium of just 7.14 percent over the issue price. This tempered enthusiasm is attributed to broader market volatility and cautious investor sentiment.

Subscription Breakdown and Investor Interest

The IPO witnessed robust demand across all investor categories, with non-institutional investors leading the charge. Retail and institutional investors also showed strong interest, reflecting confidence in Amanta’s business fundamentals.

1. Subscription details  
   - Non-Institutional Investors (NII): 209.42 times  
   - Retail Individual Investors (RII): 54.98 times  
   - Qualified Institutional Buyers (QIB): 35.86 times  

2. Anchor investment  
   - ₹37.8 crore raised from six institutional investors on August 29  
   - Anchor investors included prominent domestic and global funds  

The enthusiastic response underscores Amanta’s appeal as a mid-sized pharmaceutical player with a diversified product portfolio and expanding global footprint.

Business Profile and Financials

Founded in 1994 and headquartered in Ahmedabad, Amanta Healthcare specializes in sterile liquid pharmaceuticals and medical devices. Its products are manufactured using advanced technologies such as Aseptic Blow-Fill-Seal and Injection Stretch Blow Moulding, catering to both domestic and international markets.

Notable aspects:
- Revenue for FY25: ₹274.7 crore, slightly down from ₹280.3 crore in FY24
- Profit after tax for FY25: ₹10.5 crore, up from ₹3.6 crore in FY24
- Debt-to-equity ratio: 0.6x, indicating prudent financial management
- Export markets: Africa, Latin America, UK, and other emerging regions

The company plans to utilize IPO proceeds to expand its SteriPort manufacturing line and set up a new Small Volume Parenterals (SVP) unit in Hariyala, Kheda, Gujarat. Remaining funds will support general corporate purposes.

Expert Views and Listing Expectations

While the IPO was oversubscribed, analysts caution that the listing may not reflect the same level of exuberance. The modest GMP and broader market conditions suggest a stable but unspectacular debut.

Additional insights:
- Analysts expect listing around ₹135 per share, based on GMP trends
- Market observers note that the muted premium reflects realistic valuation
- Long-term prospects remain positive due to Amanta’s niche positioning and expansion plans

Brokerages like Ventura and Scoop Investment have recommended subscribing for long-term gains, citing the company’s unique SteriPort technology and strong export potential.

Looking Ahead

Amanta Healthcare’s IPO listing today is a moment of validation for its growth strategy and operational resilience. While the debut may be subdued, the company’s fundamentals and expansion roadmap offer promise for sustained investor interest. As trading begins, stakeholders will be watching closely to see whether Amanta can convert its IPO momentum into lasting market performance.

Sources: MSN News, CNBC TV18, Business Standard, Outlook Money, Livemint, Goodreturns.